Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...

Search for other works by this author on: ...

Search for other works by this author on: ...

The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In ...

University of Nebraska Medical Center, Omaha, NE, ...

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

CDK2 inhibitors have received some attention at the 2024 ESMO Congress, with one candidate, PF-07104091, showing combination potential with CDK4-selective blockade in HR–positive, HER2–negative breast ...

According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the ESMO Congress in Barcelona, Spain, and concurrently published, the Daiichi Sankyo/Astra Zeneca ...